Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

226,081-226,110 of 319,975

filter-aware
43
The table displays clinical trial data for NXC-201, specifically focusing on Cytokine Release Syndrome (CRS) and Immune cell associated Neurotoxicity (ICANS) across three dosage groups.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
44
The table highlights specific adverse events (CRS and ICANS) within a red dashed box.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
45
Highlights NXC-201's lower fludarabine dose (25 mg vs 30 mg) and Carvykti's longer infusion window (5-7 days vs 5 days).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
46
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
47
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
48
The slide uses a bar chart to contrast the combined annual sales of two groups of oncology drugs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
49
The slide uses three distinct bar charts to compare IMX-110 performance against standard of care or competitor drugs in preclinical mouse models.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
50
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
51
Includes survival curves (Kaplan-Meier style), tumor imaging, and median survival metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
52
Includes clinical trial data visualization with PFS (Progression Free Survival) and PD/PR thresholds.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
53
The slide uses a scatter plot to map clinical trials and a table to detail standard-of-care metrics by line of therapy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
54
The slide compares clinical outcomes for patients across different lines of treatment, emphasizing high disease control and zero drug-related toxicity.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
55
Includes logos for BeiGene and Novartis.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
56
Includes comparative size diagram of IMX-111 vs IgG antibody, bar chart of GLUT1 expression by tissue, box plot of GLUT1 expression by stage, and Kaplan-Meier survival curve.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
57
Includes two sets of charts: tumor volume line charts and survival curves.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
58
Includes multiple citations and diagrams of molecular mechanism and clinical trial results.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
59
The slide compares efficacy data for Humira, Stelara, and Entyvio against their respective placebo groups.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
60
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
61
The slide uses a process-flow style layout to connect platform capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
62
The process is presented as a non-linear, snake-like flow (1-5 left-to-right, 6-10 right-to-left).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
63
The slide uses a 3-pillar framework to categorize the platform's foundation, leading to specific product applications.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
64
Includes company logo, tagline, mission statement, date, and ticker symbol.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
01
Slide 1
Independent Bank Corp | Results Presentation Deck | 30 slidesIndependent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations 1 hit
02
Independent Bank Corp | Results Presentation Deck | 30 slidesIndependent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations 1 hit
03
Independent Bank Corp | Results Presentation Deck | 30 slidesIndependent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations 1 hit
04
Independent Bank Corp | Results Presentation Deck | 30 slidesIndependent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Problem1 hit
05
The slide uses a combination of a donut chart for composition and a combo bar-line chart for cost trends.Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Problem1 hit
06
The chart uses a dual-axis approach: left axis for interest rates (percentage), right axis for deposit balances (absolute dollars).Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Problem1 hit
07
Includes detailed breakdown of loan origination yields and rate mix (fixed vs variable/indices).Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Problem1 hit
08
The slide uses two donut charts to visualize the composition of the portfolio. Data is as of December 31, 2023.Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Problem1 hit